Basit öğe kaydını göster

dc.contributor.authorSayan, Murat
dc.contributor.authorOzguler, Muge
dc.contributor.authorYildirim, Figen Sarigul
dc.contributor.authorYildirmak, Taner
dc.contributor.authorGunduz, Alper
dc.contributor.authorDokuzoguz, Basak
dc.contributor.authorUnal, Serhat
dc.date.accessioned2020-06-21T12:18:01Z
dc.date.available2020-06-21T12:18:01Z
dc.date.issued2020
dc.identifier.issn2146-3123
dc.identifier.issn2146-3131
dc.identifier.urihttps://doi.org/10.4274/balkanmedj.galenos.2020.2019.5.89
dc.identifier.urihttps://hdl.handle.net/20.500.12712/10066
dc.description19th Annual Meeting of the European-Society-for-Clinical-Virology -- SEP 14-17, 2016 -- Lisbon, PORTUGALen_US
dc.descriptionWOS: 000526082100003en_US
dc.descriptionPubMed: 32106666en_US
dc.description.abstractBackground: Because of their similar modes of transmission, the simultaneous infection of viral hepatitis and human immunodeficiency virus are increasingly seen as a big problem related to human health. Aims: To determine the drug mutations in hepatitis B virus and/or hepatitis C virus co-infected human immunodeficiency virus-1 patients in Turkey. Study Design: Retrospective cross-sectional study. Methods: The present study was conducted between 2010 and 2017. HBsAg, anti-hepatitis C virus, and anti-human immunodeficiency vim were tested with ELISA. All anti-human immunodeficiency virus positive results by ELISA were verified for anti-human immunodeficiency virus positivity by a Western blot test, and Antihuman immunodeficiency virus positive patients with HBsAg andior anti-hepatitis C virus positivity were included in the study. Subtyping and genotypic resistance analyses were performed by population sequencing of the viral protease and reverse transcriptase regions of the human immunodeficiency virus-1 pol gene. Results: We detected 3896 human immunodeficiency virus-1 positive patients whose sera were sent from numerous hospitals across the country to our polymerase chain reaction unit for detection of drug resistance mutations and whose molecular laboratory tests were completed. Viral hepatitis co-infections were detected in 4.3% (n=170) of patients. Hepatitis B virus and hepatitis C virus co-infection were observed in 3.2% and 0.5% of all human immunodeficiency virus-I infected patients, respectively. The major human immunodeficiency virus-1 subtype detected was group M, subtype B (62.9%). However, 13.5% of drug resistance mutation motifs were found in human immunodeficiency virus-1 genomes of patients included in the study. Conclusion: Due to similar transmission routes, HIV1 patients are at risk of hepatitis B and C virus co-infection. However, antiretroviral drug resistance mutation model is similar to patients with hepatitis negative.en_US
dc.description.sponsorshipEuropean Soc Clin Virolen_US
dc.language.isoengen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.isversionof10.4274/balkanmedj.galenos.2020.2019.5.89en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCo-infectionen_US
dc.subjecthepatitis B virusen_US
dc.subjecthepatitis C virusen_US
dc.subjectHIV-1en_US
dc.subjectmolecular epidemiologyen_US
dc.titleMolecular Identification of HIV-1 in the Presence of Hepatitis B Virus and Hepatitis C Virus Co-infectionsen_US
dc.typeconferenceObjecten_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume37en_US
dc.identifier.issue3en_US
dc.identifier.startpage125en_US
dc.identifier.endpage130en_US
dc.relation.journalBalkan Medical Journalen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster